LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi announced today the immediate availability in the United States of Adenosine Injection, USP in 60 mg per 20 mL and 90 mg per 30 mL presentations.

November 3 2008--LAKE FOREST, Ill.--(BUSINESS WIRE)--Akorn, Inc. (NASDAQ: AKRX) today announced that the U.S. Food and Drug Administration has granted approval for Akorn's Abbreviated New Drug ...

Astellas currently markets Adenoscan (R) (adenosine injection), the leading pharmacologic stress agent for MPI studies in the United States. Adenoscan is indicated as an adjunct to thallium-201 ...

Adenosine Injection, a pharmacologic stress agent, is indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately. Fresenius Kabi announced the ...

A double injection of intracoronary adenosine improves myocardial reperfusion as well as early clinical outcomes in patients receiving primary percutaneous coronary intervention (PCI) for acute ...

Fresenius Kabi announced the launch of Adenosine Injection, USP, 6mg/2mL and 12mg/4mL, in single-dose Simplist ready-to-administer prefilled syringes. Fresenius Kabi announced the launch of Adenosine ...

The global Adenosine Injection market size is projected to gain market growth of ($ XX Mn), and it is estimated to reach $ XX Mn with a CAGR rate of XX% in the forecast period 2021-2030. Let’s grow ...

Indian pharmaceutical company Strides Arcolab on Tuesday said it got the United States Food and Drug Administration (FDA) approval to sell an additional package size of Adenosine injection used for ...

PALO ALTO, Calif. and DEERFIELD, Ill., April 10 -- CV Therapeutics and Astellas Pharma US, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Lexiscan(TM) (regadenoson) ...